Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grey Wolf HealthTSXV:WOLF 54 EV-to-EBITDA is 10.64 as of Aug. 21, 2026, which is 12% above its 10-year median of 9.49. GuruFocus rates TSXV:WOLF with a GF Score™ of 54/100 and a GF Value™ of C$1.09 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 512 Healthcare Providers & Services companies, Grey Wolf Health ranks worse than 50.39% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Grey Wolf Health's enterprise value is C$74.82 Mil.
Grey Wolf Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was C$7.03 Mil. Therefore, Grey Wolf Health's EV-to-EBITDA for today is 10.64.
The historical rank and industry rank for Grey Wolf Health's EV-to-EBITDA or its related term are showing as below:
TSXV:WOLF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.72 Med: 9.49 Max: 175.65
Current: 10.63
During the past 5 years, the highest EV-to-EBITDA of Grey Wolf Health was 175.65. The lowest was 1.72. And the median was 9.49.
TSXV:WOLF's EV-to-EBITDA is ranked worse than 50.39% of 512
companies
in the Healthcare Providers & Services industry
Industry Median: 10.6
vs TSXV:WOLF: 10.63
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Grey Wolf Health (TSXV:WOLF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Grey Wolf Health's PE Ratio (TTM) for today is calculated as:
Grey Wolf Health's share price for today is C$1.70.
Grey Wolf Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.054.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Grey Wolf Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Grey Wolf Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grey Wolf Health EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Grey Wolf Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Grey Wolf Health's EV-to-EBITDA falls into.
Grey Wolf Health's current Enterprise Value is C$74.82 Mil.
Grey Wolf Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$7.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grey Wolf Health (TSXV:WOLF) has a EV-to-EBITDA of 10.64 as of Aug. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Grey Wolf Health. This is 12% above median its historical median of 9.49. Over the past decade, Grey Wolf Health's EV-to-EBITDA has ranged from 1.72 to 175.65. According to the industry distribution chart, Grey Wolf Health ranks #258 out of 512 companies in the Healthcare Providers & Services industry, placing it in the top 50.4%.
Is Grey Wolf Health's EV-to-EBITDA too high?
Grey Wolf Health's current EV-to-EBITDA of 10.64 is 12% above median its 10-year median of 9.49. Over the past 10 years, this metric has ranged from a low of 1.72 to a high of 175.65. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.60. Grey Wolf Health's value of 10.64 is 0.4% above this industry median. Based on the distribution chart, Grey Wolf Health ranks #258 out of 512 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Grey Wolf Health has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Grey Wolf Health's EV-to-EBITDA compare to ZTS?
According to the Healthcare Providers & Services industry distribution chart, Grey Wolf Health ranks #258 out of 512 companies for EV-to-EBITDA. This places Grey Wolf Health in the lower half of its industry. The industry median EV-to-EBITDA is 10.60. Grey Wolf Health's value of 10.64 is 0.4% above this benchmark. Historically, Grey Wolf Health's own EV-to-EBITDA has ranged from 1.72 to 175.65 over the past decade. While the company's 10-year median is 9.49 vs. the industry median of 10.60, Grey Wolf Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.60, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grey Wolf Health's current EV-to-EBITDA of 10.64 is 0.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Grey Wolf Health. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grey Wolf Health's current EV-to-EBITDA is 10.64, which is 12% above median its own 10-year median of 9.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grey Wolf Health stock overvalued right now?
Based on GuruFocus' analysis, Grey Wolf Health (TSXV:WOLF) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.09, compared to a current price of C$1.70 — trading 56% above its estimated fair value. The current EV-to-EBITDA is 10.64, which is 12% above median its 10-year median of 9.49 and 0.4% above the Healthcare Providers & Services industry median of 10.60. Grey Wolf Health's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Grey Wolf Health (TSXV:WOLF), the current EV-to-EBITDA is 10.64 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grey Wolf Health (TSXV:WOLF) Overvalued in 2026?
Based on GuruFocus' analysis, Grey Wolf Health stock appears to be overvalued.
The current stock price of C$1.70 is trading 56% above its estimated GF Value™ of C$1.09.
GuruFocus considers Grey Wolf Health to be Significantly Overvalued.
Key valuation signals for TSXV:WOLF:
EV-to-EBITDA: 10.64 (12% above median its 10-year median of 9.49)
GF Value™: C$1.09 vs. price of C$1.70 (56% above fair value)
Industry Position: 0.4% above the Healthcare Providers & Services median (#258 of 512)
No single metric tells the full story. See the TSXV:WOLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grey Wolf Animal Health Corp focuses on sourcing, in-licensing, acquiring, and compounding branded and generic products for sale in both animal and human health markets in Canada. The Company operates through two reportable segments: the Animal Health segment, which involves the sale, marketing, and distribution of pharmaceutical, nutraceutical, and consumable products to veterinary clinics across Canada; and the Pharmacy segment, which generates the majority of revenue and focuses on compounding pharmaceuticals for both human and animal health markets.
54GF Score
Get the complete analysis for TSXV:WOLF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:WOLF has been successfully added to your 
